Antidepressants and psychotherapy: a clinical research review by Frank, Ellen et al.
his review focuses on information concerning
antidepressants and psychotherapy in the treatment of
both acute and chronic forms of unipolar depression in
the English language literature.We address the use of
combination therapy both from the outset of treatment
and in a variety of sequences,ie,we examine the advan-
tages of adding a targeted psychotherapy to an incom-
pletely effective pharmacotherapy and the advantages
of adding pharmacotherapy to an incompletely effective
psychotherapy.We do not address the use of these tar-
geted psychotherapies alone, except inasmuch as to
describe those targeted psychotherapies for which there
is evidence of their efficacy in the treatment of various
forms of unipolar depression, suggesting the potential
utility of combining them with pharmacotherapy.
Furthermore, although there is a burgeoning literature
on the advantages of adding psychotherapy to pharma-
cotherapy in the treatment of bipolar disorder and, in
particular, in the treatment of bipolar depression, the
present review does not address the use of psychother-
apy in the treatment of bipolar disorder.
Forms of targeted psychotherapy that 
have been combined or sequenced with 
antidepressant pharmacotherapy
To date, the English language literature provides evi-
dence for the efficacy of several forms of time-limited
psychotherapy in the treatment of unipolar disorder.
These include the cognitive therapy (CT; or cognitive
behavioral therapy [CBT]) of Beck and colleagues,
1,2
interpersonal psychotherapy (IPT) as developed by
Klerman and Weissman,
3,4 the cognitive-behavioral analy-
sis system of psychotherapy (CBASP) developed by
McCullough,
5,6 problem-solving therapy (PST) developed
by Gath,Catalan,Mynors-Wallis,and colleagues
7 in the
UK,and psychodynamic-interpersonal (PI) psychother-
apy (also known as Hobson’s conversational model of
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This review focuses on information concerning antide-
pressants and psychotherapy in the treatment of both
acute and chronic forms of unipolar depression in the
English language literature. In it, we address the use of
combination therapy, both from the outset of treatment
and in a variety of sequences, ie, we examine the poten-
tial advantages of adding a targeted psychotherapy to
an incompletely effective pharmacotherapy and the
potential advantages of adding pharmacotherapy to an
incompletely effective psychotherapy. The number of
research reports available to address these questions is
small relative to their importance for clinical practice.
There is a clear need for more information about the rel-
ative efficacy of pharmacotherapy–psychotherapy com-
binations or sequences versus either pharmacotherapy or
psychotherapy provided as monotherapies.   
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8 and extended by
Guthrie and Shapiro in Manchester.
9,10
For each of these treatments,there is a considerable body
of knowledge regarding their efficacy as monotherapies
in comparison with active or placebo-controlled condi-
tions.Yet,intent-to-treat response rates for either anti-
depressant pharmacotherapy or psychotherapy alone
rarely exceed 50% to 60%
11;full and sustained remission
rates are even lower.
12,13 For the severely or recurrently
depressed individual,monotherapy may be inadequate.
The neurobiological substrate of an individual’s depres-
sive illness may be too severely disturbed to be respon-
sive to psychotherapy alone.Likewise,psychosocial or
interpersonal stressors may be so extensive that phar-
macotherapy alone will not bring about full remission of
an individual’s depressive episode.Investigators consis-
tently demonstrate an increased recurrence risk for indi-
viduals who experience a partial remission, delayed
response to acute treatment,or residual symptoms post-
treatment.
14,15 For these individuals, combined psy-
chotherapy and pharmacotherapy may be the best treat-
ment modality.
16-18
Considering the empirical support for the aforemen-
tioned psychotherapies,it is not surprising that various
groups have generally chosen one of these nonsomatic
treatments to combine or sequence with pharmacother-
apy.For those not entirely familiar with CT,IPT,CBASP,
PST,or PI,a brief description of each follows.
Psychotherapy
Cognitive therapy
CT is a manualized, short-term, present-oriented psy-
chotherapy that has demonstrated robust and replicable
results,as both an acute and maintenance treatment for
depression and residual symptoms.
17,19-21 Acute CT
involves typically 12 to 26 weekly sessions.
CT, as developed by Beck,
1 focuses on an individual’s
cognitive mediation and how one’s thoughts and beliefs
influence one’s feelings and behavior.For depressed indi-
viduals,a clinician explores the relationship between neg-
ative thinking and the depressive state;specifically,how
one’s thoughts and beliefs exert influence on one’s feel-
ings and behavior.The primary goal of CT is to change
the depressed person’s negative view of the world,self,
and future.Other goals include increasing the frequency
of activities that bring about a sense of mastery or plea-
sure,highlighting how pessimistic,illogical,or maladap-
tive thinking contributes to psychological distress and
functioning,and helping generate strategies for dealing
with the current symptoms,problems,and triggers.
Friedman and Thase
22 explain that CT stresses collabo-
rative empiricism.That is,the clinician guides the patient
into developing a scientific attitude toward testing the
validity or effectiveness of certain thoughts or behaviors.
Together,the clinician and patient develop hypotheses
about cognitions and behaviors,determine ineffective or
erroneous patterns by examining data,explore alterna-
tives,and,finally,change cognitions or behaviors to be
more effective and positive.Socratic questioning,a pri-
mary strategy of CT,teaches the use of rationality and
inductive reasoning.Initial CT techniques include psy-
choeducation, behavioral activation, identifying and
modifying automatic thoughts via Socratic questioning
or thought recording,and the reduction in symptoms via
behavioral techniques (eg, desensitization, relaxation
training,social skills training,exposure and flooding,and
distraction).
1 Intermediate strategies may include exam-
ining data,generating alternatives,rehearsing and prac-
ticing new behaviors and cognitions,and modifying core
beliefs or “schemas.” Beck
1 conceptualizes schemas as
cognitive templates that are learned early in life and
guide perception, organize experience, and shape the
probability of certain kinds of responses in specific situ-
ations.Schemas often include dysfunctional attitudes that
may increase one’s vulnerability to a first episode or
recurrence of depression.
19
Interpersonal psychotherapy
Like CT, IPT is a manualized, short-term, present-ori-
ented psychotherapy that has demonstrated robust and
replicable results, as both an acute and maintenance
treatment for depression.
3,22-24 Acute IPT typically
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Selected abbreviations and acronyms
CBASP cognitive-behavioral analysis system of 
psychotherapy
CT cognitive therapy
IMP imipramine
IPT interpersonal psychotherapy
IPT-M maintenance interpersonal psychotherapy
PI psychodynamic-interpersonal (psychotherapy)
PST problem-solving therapy
TCA tricyclic antidepressantinvolves 16 to 24 weekly sessions. Recently, however,
investigators have begun testing the relative efficacy of
a briefer, 8-session, course of IPT.
25 Often, in cases of
recurrent depression,monthly or biweekly continuation
or maintenance sessions are recommended for at least 6
months following remission.
23
IPT was originally developed in a research context by
Klerman and colleagues as part of a so-called mainte-
nance treatment trial beginning in 1968.
26,27 This first
efficacy study of IPT would probably be considered a
continuation treatment trial today. IPT was subse-
quently codified as an acute treatment by Klerman et
al
4,28 and as a maintenance treatment by our research
group.
23,29
The theoretical rationale for IPT derives from the rela-
tionship between interpersonal distress or problems in
social role functioning and depressive illness.IPT makes
no etiological assumptions, ie, no assumptions about
whether interpersonal distress causes depression or
depression causes interpersonal distress, but rather
assumes that when depression is present there are almost
always problems in interpersonal relationships or social
role functioning,and that the amelioration of those prob-
lems is likely to result in an amelioration of depressive
symptoms as well as an improvement in functioning.The
techniques of IPT were developed to manage four basic
interpersonal problem areas:(i) unresolved grief;(ii) role
transitions;(iii) interpersonal role disputes;and (iv) inter-
personal deficits (see Klerman et al
4 and Weissman et al
3
for an explanation of the theoretical background and
development of IPT). The major goals of IPT are
achieved by ascertaining with the patient which of these
four problems was associated with the onset of the cur-
rent episode of depression and,subsequently,by working
with the patient to renegotiate interpersonal difficulties
associated with the primary problem area.IPT strategies
include role-play,communication analysis,and direct sug-
gestion.
Although maintenance interpersonal psychotherapy
(IPT-M) preserves the four distinctive problem areas and
employs the strategies and techniques of IPT,it differs in
that its primary goal is prevention of recurrence and it is
conceptualized as a long-term rather than an acute inter-
vention.Because of the length of maintenance treatment,
a number of problem areas are typically addressed and
the therapist often focuses on long-standing patterns of
interpersonal behavior that appear nonadaptive for the
patient.
23
Cognitive behavioral analysis system of psychotherapy
CBASP is a manualized psychotherapy specifically
designed to help severely and chronically depressed indi-
viduals build new problem-solving and relationship
skills.
6 Hirschfeld et al
30 explain that CBASP is similar to
IPT, inasmuch as treatment focuses on interpersonal
interactions,but is substantially more directive and struc-
tured than IPT, and frequently focuses on the thera-
pist–patient interactions.CBASP is an acute treatment
that is scheduled twice weekly for the first 4 weeks,and
weekly thereafter until week 12,with a maximum session
allowance of 20 sessions.
6
CBASP evolved from McCullough’s view of the specific
cognitive correlates of dysthymia or chronic depression.
6
He argued that individuals with dysthymia tend to have
a series of dysfunctional attitudes, particularly with
respect to dependence,competence,and trust.They also
tend to have an attributional style that views these prob-
lems as internal,global,and irreversible.Their sense of
self-efficacy relative to that of the general population is
low and they tend to have a highly reactive response to
problems and stressors consistent with Eysenck’s concept
of neuroticism.The primary goal of CBASP is to teach
patients to understand the consequences of their situa-
tional behavior and address the interpersonal difficulties
and cognitive correlates of dysthymia through situational
analysis, interpersonal discrimination exercises, and
behavioral skill training and rehearsal.
Problem-solving treatment
Problem-solving treatment (PST) was developed at
Oxford University by Gath, Mynors-Wallis, and col-
leagues as a very brief form of psychotherapy to be used
in the treatment of major depressive disorders in primary
care settings.
7,31They developed PST with an eye toward
reducing emotional symptoms by addressing “problems
with living.”
7 The primary goal of PST is to increase
patients’ sense of mastery and self-control. PST is a
three-phased treatment intended to be carried out in six
sessions over 12 weeks.
31 Mynors-Wallis
31 explains that
the goal of phase 1 is linking symptoms to problems;
phase 2 is clarifying and defining problems;and phase 3
is attempting to solve problems in a structured way.
Phase 3 includes sessions focused on finding ways to
address the problem and reviewing “homework assign-
ments”related to the resolution of the problem,and ses-
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and generalizing the strategy to other problems the
patient might wish to confront.
Psychodynamic interpersonal therapy
PI therapy, originally termed Hobson’s conversational
model of psychotherapy,was developed by Hobson
8 and
has been more recently studied by other investigators,
most notably Guthrie and Shapiro.Guthrie
9,10 describes PI
as an integrative model of therapy that combines psycho-
dynamic,humanistic,and interpersonal theory and tech-
niques.A typical course of PI is three to eight sessions.
Unlike IPT,the primary tools of PI include transference
and metaphors.
32 Much like CBASP,the therapist–patient
relationship is core to PI and important to the explo-
ration of the connection between depressed mood and
problematic interpersonal relationships.The therapist
makes no assumptions concerning the patient’s problems
or feelings,adopting a stance of individuality.Together,
the therapist and client develop negotiation and com-
munication skills.The goal of a PI therapist is to under-
stand the patient’s personal,individual feelings concern-
ing problems and the consequence or influence of these
problems,and to offer interventions only in a tentative
and nondogmatic way.
Goals of treatment of unipolar disorders
In trying to understand the efficacy of psychotherapy,
pharmacotherapy, combinations, and sequences, it is
important to be clear about what the goals of treatment
are in the management of unipolar disorders.Although
nearly 50% to 60% of depressed outpatients will respond
and experience a meaningful improvement in response
to a first trial of antidepressant pharmacotherapy,
33 only
1 in 3 patients will experience a full and complete remis-
sion of their symptoms and depressive episode.
12 The
goals of treatment should extend beyond response to a
full and sustained remission of symptoms and an
improvement in psychosocial functioning.
34Ample evi-
dence points to the negative consequences of treatments
that fail to target such complete remission.Thase
15 has
demonstrated an increased recurrence risk for individ-
uals who experience a partial remission, delayed
response to acute treatment,return of symptoms during
continuation treatment or within 1 year post-treatment,
or residual symptoms post-treatment.
Researchers have demonstrated that baseline severity
and chronicity of the affective disorder substantially
undermines treatment response and increases the risk of
recurrence.Greater depression severity at baseline gen-
erally predicts a poorer response to pharmacotherapy
35
and/or psychotherapy.
36 Duration of the index episode
and the number of prior episodes are the strongest base-
line predictors of the subsequent well interval.
35,37-41
The presence of Axis I comorbidity,both at the syndro-
mal and the subsyndromal level, impedes the achieve-
ment of full remission.Panic or anxiety symptoms or dis-
order are particularly pernicious in this respect.
42-45Axis
II comorbidity has also been found by numerous inves-
tigators to be associated with incomplete remission of
depression.
35,46-48To some extent,the association of both
of these forms of comorbidity (Axis I and Axis II) with
incomplete remission may represent an artifactual infla-
tion of depression rating scale scores via the presence of
symptoms associated with the Axis I or Axis II condition.
However,there also are well-articulated descriptions of
how,for example,anxiety disorders or subsyndromal anx-
iety conditions and Axis II conditions might interfere
with obtaining the full benefit from a treatment such as
CT or IPT.
49
More recently,Katon and colleagues
50,51 have focused on
the extent to which medical comorbidities,such as dia-
betes (Axis III conditions),may interfere with remission
of depression.Again,some of this may be artifact caused
by inflation of depression scores or by somatic symptoms
associated with a comorbid medical condition. On the
other hand, there are specific hypothesized routes
through which medical comorbidity might interfere with
either pharmacotherapy or psychotherapy.Somatic pre-
occupation may preclude the individual’s ability to focus
on the specific work involved in the psychotherapy,
whereas the medical condition or the pharmacological
treatment of the medical condition may interfere with
the metabolism of antidepressant pharmacotherapy.
Finally,failure to adhere to the requirements of either a
pharmacotherapeutic or a psychotherapeutic regimen
can certainly interfere with the achievement of full remis-
sion of symptoms.
Psychotherapy and pharmacotherapy combinations and
sequences also have a clear role in the prevention of
recurrence,another key goal of treatment of unipolar dis-
orders. Since we now recognize that the majority of
unipolar depressions are recurrent, perhaps the most
challenging part of depression treatment is that which
Clinical research
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we describe below,it is here that pharmacotherapy–psy-
chotherapy combinations and sequences have shown
themselves to be particularly valuable approaches to
treatment.
Combination acute treatment: achieving
remission and return of function
As noted above, efforts to achieve full remission and
return of function have encompassed the evaluation of
combination therapy in comparison with either pharma-
cotherapy or psychotherapy monotherapy as well as
treatment sequences. The literature on the benefit of
combining pharmacotherapy with psychotherapy from
the outset of the treatment is relatively small in terms of
randomized controlled trials.We know much less than we
should about this approach to treatment on an empirical
basis.
Hollon et al
52 suggest that combined treatments may con-
fer additive benefits because the strengths of each modal-
ity are promoted while the weaknesses of each modality
are minimized.Thus, response and remission rates for
combined treatment should be superior to those of either
treatment modality as a monotherapy.They argue that
combined treatment increases the magnitude,probabil-
ity,and breadth of clinical response.Adding drug therapy
to psychotherapy may bring about a more rapid relief of
symptoms than psychotherapy alone, permitting the
patient to participate more productively in psychother-
apy (Thase ME,personal communication).Conversely,
adding psychotherapy to drug therapy may increase
medication adherence,decrease the presence and risk of
residual symptoms following drug discontinuation,and
facilitate the patient’s development of healthy coping
skills.
53
Thase has argued that combination treatment as a gen-
eral approach for the treatment of unipolar depression
has yet to receive adequate empirical support.While the
Agency for Health Care Policy and Research guideline
supports the use of combined treatments for depressive
disorders,
54 Thase and Howland believe it is best indi-
cated for patients with severe, refractory, or incapaci-
tating mood and anxiety disorders.
55 Below, we review
the relatively small number of randomized controlled
trials in the English language literature that test the rel-
ative efficacy of monotherapies and polytherapies for
depression.
Comparing monotherapy and polytherapy
The study by Klerman et al in 1974 examined the effects
of 8 months of psychotherapy in comparison with con-
tinued pharmacotherapy in 150 depressed women who
had been receiving amitriptyline therapy for 4 to 6
weeks.
26 Patients then received weekly IPT,medication,
combination IPT and medication, or placebo and no
therapy.Relapse rates were highest for patients receiv-
ing placebo alone (36%).Relapse rates in the other three
active treatment groups were 12% on medication alone,
16.7% on IPT alone, and 12.5% on combined IPT and
medication. This was one of the first controlled trials
reported in the literature examining the protective capac-
ity of psychotherapy.
The first combined treatment trial of cognitive therapy
was conducted by Blackburn and colleagues in Scotland
in 1981.
56 They compared CT, tricyclic antidepressant
(TCA) therapy,and CT combined with TCA (CT+TCA)
among 64 hospital outpatients or general practice
patients diagnosed with recurrent depression (≥1 previ-
ous episode).After 12 to 20 weeks of acute treatment,
among the hospital outpatients, response rates (50%
reduction in the Hamilton Rating Scale for Depression
[HRSD]) suggested that CT was minimally more effec-
tive than TCA, and CT+TCA was more effective than
monotherapy. For general practice patients, response
rates were equivalent for the CT and CT+TCA groups,
but significantly less for the TCA group.In a follow-up
report, Blackburn et al
57 reported that TCA was less
effective than CT or CT+TCA for sustaining remission
in both the hospital outpatient and general practice
groups.They note that TCA alone may have been less
effective than the two other conditions because of poor
medication adherence;plasma levels were not monitored
during the trial. Two years of naturalistic follow-up
revealed that no patients receiving CT+TCA relapsed
during the first 6 months of follow-up, compared with
30% in the TCA group and 6% in the CT group.Despite
a small sample size,Blackburn et al’s results suggested to
many that combination treatment may bring about the
greatest change and improvement among depressed indi-
viduals.
58
Our group has examined the efficacy of maintenance
medication and IPT in preventing recurrences.
29 The
Pittsburgh Study of Maintenance Therapies in Recurrent
Depression contrasted IPT-M with maintenance phar-
macotherapy (imipramine [IMP]),combination pharma-
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(placebo and no therapy) over a period of 3 years in
depressed patients who had clear histories of recurrent
depression (at least three episodes; sample mean was
seven episodes) and had been treated acutely with a
combination of IPT and IMP. Active medication pro-
vided the best prophylaxis, with or without IPT-M. No
advantage was observed for the combination;however,
survival time without a new episode of major depression
following discontinuation of medication was significantly
and positively related to monthly IPT-M alone or with
a placebo tablet.
We conducted a similar placebo-controlled study of
maintenance pharmacotherapy and psychotherapy (IPT)
in 180 geriatric patients with nonpsychotic unipolar
major depression.
59 Patients were treated acutely with
nortriptyline (NTP) and IPT.After 16 weeks of stabilized
depression scores, patients were randomly assigned to
one of four maintenance therapy conditions:(i) medica-
tion clinic plus NTP;(ii) medication clinic plus placebo;
(iii) IPT-M plus NTP; or (iv) IPT-M plus placebo.
Survival analyses suggest that maintenance NTP and IPT,
together and singly,is superior to medication clinic visits
and no pharmacotherapy in preventing or delaying a
depressive recurrence.Patients assigned to the combined
treatment condition had the best outcome, with 80%
remaining depression-free during the 3-year maintenance
period.
A 1997 analysis involving patients from several studies
conducted at Western Psychiatric Institute and Clinic
60
revealed that,among 595 patients experiencing a unipo-
lar major depressive episode, for the more severely
depressed patients, remission rates (HRSD<7 for 4
weeks) were higher for those receiving concurrent IPT
and antidepressant pharmacotherapy with IMP than
were remission rates for CT or IPT alone (43% versus
25%, P=0.001). For the less severely ill, combination
treatment had no additive effect.
Keller et al
5 demonstrated the superiority of combination
treatment among 681 patients with chronic depression
(episode exceeds 2 years).In this trial,85% of patients
treated with combined CBASP and nefazadone
(CBASP+NFZ) experienced a response during acute-
phase treatment compared with 55% of patients treated
only with NFZ and 52% of patients treated only with
CBASP (P=0.001). Despite impressive response rates
after 12 weeks,many patients experienced residual symp-
toms.
5
Results from one study are less than definitive concern-
ing the efficacy of combination treatment.Hollon et al
52
compared CT and IMP as monotherapies with combined
CT and IMP among 107 patients (only 64 completed the
study) with major depression.They found no significant
differences in acute-phase response rates and no signif-
icant differences in full remission rates,although there
was a trend among individuals (who completed the
study) receiving combined treatment (75%) to reach and
sustain remission more frequently than individuals
receiving monotherapy (50% CT,56% IMP).For the 64
patients who completed the study,Evans et al
61 report no
significant differences at 2-year follow-up.
Sequential treatment strategies
Fava
62 contends that the goal of sequential treatment
strategies is to increase or boost the therapeutic effect
of a first-treatment by augmenting with a second treat-
ment.Hence,the sequencing of treatment is dependent
upon the degree of acute treatment response. Fava
62
details four clinical applications of sequential treat-
ments: (i) changing the orientation of psychotherapy
when a first orientation of psychotherapy has not
achieved treatment goals;(ii) introducing a second med-
ication when the first medication has not achieve ade-
quate symptom relief; (iii) introducing psychotherapy
when medication alone has not been fully effective;and
(iv) introducing medication when psychotherapy alone
has not been fully effective.Only in the past decade have
investigators really begun to investigate the benefits of
sequential treatment strategies.
Fava and colleagues investigated a sequential approach for
the treatment of residual symptoms and recurrence risk.
63,64
After initial treatment with antidepressant medication,40
patients (who demonstrated an initial, but not full
response to medication) were randomly assigned to
receive 20 weeks of CBT and pharmacotherapy or clinical
management and pharmacotherapy.All patients eventu-
ally discontinued pharmacotherapy. Patients were
instructed to call immediately if any new symptoms
appeared and were guaranteed a renewed course of drug
therapy in the event of a relapse.Fava et al
17 found that the
CBT group had significantly fewer residual symptoms fol-
lowing drug discontinuation than the clinical management
group.More interestingly,the benefits of short-term CBT
after successful antidepressant treatment had a substantial
effect on recurrence risk.Treatment gains persisted at year
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on relapse and recurrence prevention).
63,64 In another trial,
Fava et al
65 added CBT to patients who experienced a
response but not a remission to sertraline and found sim-
ilar results.
Paykel et al
66 randomly assigned 158 patients with major
depression who had experienced only partial remission
with at least 8 weeks of antidepressant treatment (either
fluoxetine or a TCA) to continue monotherapy with the
antidepressant or receive 20 sessions of CT in addition to
continuing antidepressant treatment for 1 year.While
47% of patients receiving only antidepressant treatment
relapsed, only 29% of patients receiving combination
treatment relapsed (P=0.02).
Our own group observed a substantial advantage for
sequencing IPT and the combination as opposed to com-
bination therapy from the outset in an effort to achieve
sustained remission.
67We noted that when combination
therapy was provided from the outset of treatment to a
group of patients with moderately severe episodes of
recurrent depression,66% achieved sustained remission
of symptoms,while when we took the approach of adding
pharmacotherapy to the IPT of patients who appeared
unable to achieve full remission with IPT alone,78.6%
achieved remission (x
2=6.55,P=0.02).Our interpretation
of this finding is that the failure to achieve remission with
IPT monotherapy stands as a kind of marker for those
most likely to benefit from the addition of pharma-
cotherapy.
On the basis of our results and those of other groups,we
see the sequencing of monotherapy followed by combi-
nation when monotherapy alone fails to bring about
remission as a particularly efficient strategy and one that
is likely to lead to considerable cost savings as compared
with a strategy that involves treating all patients with a
pharmacotherapy–psychotherapy combination from the
outset of acute treatment.
Maintenance treatment: sequential strategies
to preventing relapse and recurrence
As noted above, Fava and colleagues have been inter-
ested in the protective effect of the addition of cognitive
therapy for patients with unipolar depression. For
instance,in a series of reports investigating the long-term
protective effects of CBT,Fava and colleagues
63,64 demon-
strated that providing a short course of CT to patients
with highly recurrent depression and who had already
responded to antidepressant treatment was additive:25%
of patients in the CT group relapsed compared with 80%
of patients in the clinical management group by year 2.
In another report,Fava and colleagues
17 demonstrated
that,following successful antidepressant treatment and
discontinuation,only 35% of patients who received CT
during drug discontinuation relapsed compared with
70% of patients who received only clinical management.
Our own group has examined the benefit of maintenance
IPT in combination with pharmacotherapy in both
midlife and elderly patients.Interestingly,we found no
advantage whatever for sustained combination treatment
in comparison to maximally dosed pharmacotherapy
alone in the prevention of recurrence among midlife
patients.
29 In a subsequent trial of elderly patients aged
60 to 80 years with recurrent depression,Reynolds et al
59
reported a modest advantage for the combination over
maintenance pharmacotherapy alone in this more brittle
population.
Future directions
As we proceed into the 21st century,there is a clear need
for more information about the relative efficacy of phar-
macotherapy–psychotherapy combinations or sequences
versus either pharmacotherapy or psychotherapy provided
as monotherapies.This is a particularly striking lack inas-
much as we know that the majority of private practition-
ers,at least in the USA,still see combination as the ideal
treatment,and combination therapy is recommended in
the treatment guidelines promulgated by the American
Psychiatric Association. Not only do we need to know
whether combinations are superior to monotherapies,but
we also need to know how combination treatment is best
practiced,ie,what are the advantages and disadvantages
to both treatments being provided by a single practitioner
versus pharmacotherapist–psychotherapist treatment
teams working in coordination versus completely inde-
pendent practitioners providing pharmacotherapy and
psychotherapy to the same individual.While the fully inte-
grated approach in which a single clinician provides both
pharmacotherapy and psychotherapy may represent the
most efficient method,it may not be the most economical
method of providing combination treatment.Fully inte-
grated teams of practitioners who are in continuous com-
munication would appear to have multiple advantages
over independent practitioners providing pharmacother-
apy and psychotherapy separately to the same patient.
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In addition to more information about the benefits of
combining classic forms of the empirically validated psy-
chotherapies with pharmacotherapy,there is increasing
interest in adaptations of these treatments designed to
address specific patient needs.Our own research group,
for example,has taken on the challenge of adapting IPT
to the needs of patients with syndromal and subsyndro-
mal anxiety comorbidity.Results of an initial open study
suggest that this adaptation,which focuses particularly
on the ways in which anxiety may interfere with the abil-
ity to make use of and benefit from traditional IPT,clear
advantages of this treatment over traditional IPT both
when used as a monotherapy and when offered in a
sequential design that permits the addition of pharma-
cotherapy.
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Antidepresivos y psicoterapia: 
una revisión de la investigación clínica
Esta revisión está centrada en la información rela-
cionada con los antidepresivos y la psicoterapia en
el tratamiento de las formas tanto aguda como cró-
nica de la depresión unipolar en la literatura en
inglés. En ella se consignó el uso de la terapia com-
binada desde el principio del tratamiento y en una
variedad de secuencias, es decir, se examinaron las
potenciales ventajas de agregar una psicoterapia
específica a una farmacoterapia no totalmente
efectiva y las potenciales ventajas de agregar far-
macoterapia a una psicoterapia no totalmente efi-
caz. El número de reportes de investigación dispo-
nibles para aclarar estas preguntas es pequeño en
relación con su importancia en la práctica clínica.
Existe una clara necesidad de más información
acerca de la eficacia relativa de las combinaciones
farmacoterapia-psicoterapia o secuencias versus ya
sea farmacoterapia o psicoterapia ofrecidas como
monoterapia.  
Antidépresseurs et psychothérapie : 
revue de recherche clinique
Cet article se penche sur des informations concer-
nant les antidépresseurs et la psychothérapie dans
le traitement des formes à la fois chronique et
aiguë de la dépression unipolaire dans la littérature
anglaise. Nous étudions ici l’usage d’une association
à la fois dès le début du traitement et dans diverses
circonstances, par exemple, nous examinons les
avantages potentiels de l’association d’une psycho-
thérapie à une pharmacothérapie insuffisamment
efficace et les avantages potentiels de l’association
d’une pharmacothérapie  à une psychothérapie
insuffisamment efficace. Le nombre de rapports
d’études disponibles pour traiter de ces questions
est faible par rapport à leur importance dans la pra-
tique clinique. Nous avons besoin de plus d’infor-
mations sur l’efficacité relative des associations
pharmacothérapie-psychothérapie ou sur les sché-
mas présentant la pharmacothérapie ou la psycho-
thérapie comme des monothérapies.
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